CY1124030T1 - Συνθεσεις που περιλαμβανουν αμινοξεα για χρηση στην προληψη και θεραπεια ηπατικων νοσων - Google Patents

Συνθεσεις που περιλαμβανουν αμινοξεα για χρηση στην προληψη και θεραπεια ηπατικων νοσων

Info

Publication number
CY1124030T1
CY1124030T1 CY20211100249T CY211100249T CY1124030T1 CY 1124030 T1 CY1124030 T1 CY 1124030T1 CY 20211100249 T CY20211100249 T CY 20211100249T CY 211100249 T CY211100249 T CY 211100249T CY 1124030 T1 CY1124030 T1 CY 1124030T1
Authority
CY
Cyprus
Prior art keywords
prevention
treatment
amino acids
compositions
liver diseases
Prior art date
Application number
CY20211100249T
Other languages
English (en)
Inventor
Paolo Luca Maria Giorgetti
Original Assignee
Professional Dietetics International S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Professional Dietetics International S.R.L. filed Critical Professional Dietetics International S.R.L.
Publication of CY1124030T1 publication Critical patent/CY1124030T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Σύνθεση για χρήση στην πρόληψη και/ή θεραπεία μίας ηπατικής νόσου σε ένα θηλαστικό, όπου η σύνθεση περιλαμβάνει ένα δραστικό παράγοντα, όπου ο εν λόγω δραστικός παράγοντας περιέχει τα αμινοξέα λευκίνη, ισολευκίνη, βαλίνη, θρεονίνη, λυσίνη και τα καρβοξυλικά οξέα κιτρικό οξύ, σουκινικό οξύ, μηλικό οξύ.
CY20211100249T 2018-06-27 2021-03-22 Συνθεσεις που περιλαμβανουν αμινοξεα για χρηση στην προληψη και θεραπεια ηπατικων νοσων CY1124030T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102018000006725A IT201800006725A1 (it) 2018-06-27 2018-06-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche

Publications (1)

Publication Number Publication Date
CY1124030T1 true CY1124030T1 (el) 2022-05-27

Family

ID=63491976

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100249T CY1124030T1 (el) 2018-06-27 2021-03-22 Συνθεσεις που περιλαμβανουν αμινοξεα για χρηση στην προληψη και θεραπεια ηπατικων νοσων

Country Status (22)

Country Link
US (1) US20210260011A1 (el)
EP (1) EP3586837B1 (el)
JP (1) JP7347744B2 (el)
KR (1) KR20210025611A (el)
CN (1) CN112334129A (el)
AU (1) AU2019293293A1 (el)
BR (1) BR112020026431A2 (el)
CA (1) CA3104839A1 (el)
CL (1) CL2020003209A1 (el)
CY (1) CY1124030T1 (el)
DK (1) DK3586837T3 (el)
EA (1) EA202092749A1 (el)
ES (1) ES2858355T3 (el)
IT (1) IT201800006725A1 (el)
LT (1) LT3586837T (el)
MX (1) MX2020013471A (el)
PH (1) PH12020552254A1 (el)
PL (1) PL3586837T3 (el)
RS (1) RS61613B1 (el)
SG (1) SG11202012297XA (el)
WO (1) WO2020003013A1 (el)
ZA (1) ZA202007834B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700087376A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT202000000454A1 (it) * 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
WO2022266480A1 (en) * 2021-06-17 2022-12-22 Axcella Health Inc. Methods of predicting liver fat content and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001521002A (ja) * 1997-10-24 2001-11-06 コーネル リサーチ ファンデーション インク． 脳の代謝機能不全のための栄養補充剤
WO2007049818A1 (ja) * 2005-10-27 2007-05-03 Ajinomoto Co., Inc. 抗脂肪肝、抗肥満及び抗高脂血症用組成物
JP2007161642A (ja) * 2005-12-14 2007-06-28 Kyowa Hakko Kogyo Co Ltd アルコール性肝障害抑制剤
US20130084378A1 (en) * 2011-09-30 2013-04-04 Daesang Corporation Amino acid seasoning compositions comprising l-glutamic acid and l-lysine
US9597367B2 (en) * 2013-04-19 2017-03-21 Bioventures, Llc Methods for improving muscle and heart function
JP6013670B1 (ja) * 2014-12-09 2016-10-25 株式会社日本自然発酵 老化抑制剤
US20180161296A1 (en) * 2015-05-11 2018-06-14 Newcastle Innovation Limited Amino acid supplementation

Also Published As

Publication number Publication date
MX2020013471A (es) 2021-02-18
WO2020003013A1 (en) 2020-01-02
ZA202007834B (en) 2021-10-27
JP2021529731A (ja) 2021-11-04
PL3586837T3 (pl) 2021-09-13
DK3586837T3 (da) 2021-03-01
SG11202012297XA (en) 2021-01-28
JP7347744B2 (ja) 2023-09-20
KR20210025611A (ko) 2021-03-09
IT201800006725A1 (it) 2019-12-27
CL2020003209A1 (es) 2021-06-04
CA3104839A1 (en) 2020-01-02
CN112334129A (zh) 2021-02-05
AU2019293293A1 (en) 2021-01-14
LT3586837T (lt) 2021-05-10
PH12020552254A1 (en) 2021-08-16
RS61613B1 (sr) 2021-04-29
BR112020026431A2 (pt) 2021-03-30
EP3586837A1 (en) 2020-01-01
ES2858355T3 (es) 2021-09-30
EP3586837B1 (en) 2020-12-23
EA202092749A1 (ru) 2021-06-23
US20210260011A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
CY1124030T1 (el) Συνθεσεις που περιλαμβανουν αμινοξεα για χρηση στην προληψη και θεραπεια ηπατικων νοσων
CO2020009625A2 (es) Inhibidor de fap
PH12020500190A1 (en) Compositions comprising amino acids for use in the treatment of mitochondrial dysfuntion-related diseases
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
CY1125104T1 (el) Συνθεσεις φλαγελλινης entrecoccus για χρηση στη θεραπεια
MX2020008208A (es) Agentes de unión a fibroblastos y uso de estos.
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
MX2019001850A (es) Formulaciones para administracion oral de principios activos.
MX2017006748A (es) Composiciones de aminoácidos para el tratamiento de síntomas de enfermedades.
CY1125085T1 (el) Αρωματικα αμιδια καρβοξυλικου οξεος ως ανταγωνιστες υποδοχεα βραδυκινινης β1
CO2020016480A2 (es) Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
CL2017003201A1 (es) Variantes de il-37
EA202090945A1 (ru) Анти-msln-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
MX2020001084A (es) Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial.
CY1117536T1 (el) Συνθεσεις που περιλαμβανουν αμινοξεα για τη θεραπεια της χρονιας αποφρακτικης πνευμονοπαθειας
CL2021002131A1 (es) Uso de composiciones con aminoácidos para el tratamiento de lesiones del sistema nervioso central.
CL2022001779A1 (es) Composiciones que comprenden aminoácidos para la prevención y/o el tratamiento del cáncer
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
CY1125395T1 (el) Αντιμικροβιακες συνθεσεις με αναβραζουσες ουσιες